Background: The role of the adipokines in the pathogenesis of aortic stenosis (AS) is not well
INTRODUCTION
Adipokines are involved in various inflammatory and metabolic processes, including atherosclerosis, hypertension and dyslipidemia. Their standard panel includes adiponectin, leptin resistin and visfatin.
Adiponectin has antiatherogenic and anti-inflammatory effects on endothelial cells and macrophages [1, 2] , which are caused by an increase in nitrix oxide (NO) production, a reduction of adhesion molecules in the endothelial cells, inhibition of macrophages cytokine production and foam cell formation supression [3] [4] [5] . Clinical studies implicate hypoadiponectinemia in the pathogenesis of diabetes mellitus (DM) type 2, arterial hypertension (HA), coronary artery disease (CAD) and left ventricular (LV) hypertrophy [6] [7] [8] [9] .
Leptin, in turn, may have an impact on cardiac hypertrophy and may be associated with an increased cardiovascular risk (CVR) as plasma leptin concentrations were shown to be elevated in patients with LV dysfunction and heart failure [10] [11] [12] .
Resistin, which has primarily been suggested as a hormone that potentially links obesity to DM, was later proved to regulate the processes of the atherosclerosis and cardiovascular disease as well [13, 14] .
Visfatin, which was originally described as a protein secreted by visceral fat that mimics insulin effects, turned out to have a relationship with cardiovascular diseases. It can promote foam cell formation and angiogenesis [15] [16] [17] . Elevated visfatin serum levels were found in patients with acute myocardial infarction [18] .
Adipokines may thus be considered to be a network that influences metabolic states and has the potential to impact directly upon the metabolic homeostasis of a system. Their role in other pathological cardiovascular conditions is not yet well known. Assuming that there are some similarities between the pathophysiology of calcific aortic valve (AV) disease and atherosclerosis, those proteins may likewise play a potential role in its development. Moreover, in aortic stenosis (AS) with a low-gradient and preserved ejection fraction (EF), a clinical profile of patients with a higher incidence of obesity, HA and increased peripheral vascular resistance may especially be associated with adipokines abnormalities [19, 20] .
Thus, the aim of this study was to evaluate the relationship between adipokines and the clinical characteristics as well as echocardiographic indices and noninvasive markers of vascular remodeling in patients with severe AS with preserved EF. AS and any symptoms that are related to AS. The exclusion criteria included actual indications for coronary revascularization, segmental wall motion abnormalities, a bad acoustic window (5 or more segments that could not be analyzed), non-sinus rhythm, a bicuspid AV, moderate/severe mitral regurgitation, acute and chronic inflammatory diseases including myocarditis and endocarditis (in the three preceding months), NYHA IV, dilatation of the aortic root, Marfan syndrome, acute coronary syndromes, recurrent supraventricular and ventricular arrhythmias, acute and chronic kidney disease (glomerular filtration rate < 60 mL/min/1.73 m 2 ), malignancies, autoimmune diseases, immunosuppressive therapy, coexisting psychiatric or neurological disorders and alcohol or drug abuse. The study protocol was approved by the local Bioethics Committee. Each patient gave written consent to participate in the study.
METHODS Population

Clinical data
The clinical characteristics of the patients in the study included their clinical status (NYHA/CCS class), anthropometric data (height, BMI, waist to hip ratio [WHR]), a physical examination and medical history (concomitant diseases, pharmacotherapy and smoking status).
Body composition was determined by an impedance analysis using Bodystat.
Laboratory tests
Blood samples (10 mL) were drawn from the peripheral vein from patients in the supine decubitus position in the morning after an overnight fast. Total cholesterol (TC), high-(HDL) and low-density lipoprotein cholesterol (LDL) fractions, triglycerides (TG) and creatinine serum concentrations were measured using routine methods.
Serum levels of adipokines (intra-assay variability ranged: 6-9%) were measured using an enzyme-linked immunosorbent assay. A single-use kit was used in order to avoid inter-assay variability.
Coronary angiography
Coronary angiography was performed in all patients. A diagnosis of CAD was established in cases of a ≥ 70% diameter narrowing in at least one of the three major epicardial coronary arteries.
Ultrasound assessment
Two-dimensional transthoracic echocardiography (2D TTE) was performed in all of the patients by an experienced sonographer according to guidelines of the European Society of Echocardiography [21] . An ultrasound system (GE Vivid 9) equipped with a 3.5-1.75 MHz transthoracic transducer was used for all of the patients. 
Left ventricular geometry and function
Two
Severity of aortic valve stenosis/effective orifice area of the implanted prosthesis
Maximal (Pmax) and mean (Pmean) transvalvular pressure gradients were obtained using a modified Bernoulli equation and the effective orifice area (EOA) was measured using the continuity equation. The LV outflow tract (LVOT) dimension was measured three to four times and finally the mean LVOT value was used in the automatically calculated EOA. In order to avoid any mistakes, we compared EOA calculated by VTI and the Vmax and SV measured by Simpson's formula and this was obtained using the Bernoulli equation. The values of the EOA were indexed for BSA. The valvuloarterial impedance (Zva) was calculated according to the recommended equation [21] .
Noninvasive markers of vascular remodeling
Flow-mediated dilatation (FMD)
The examinations were performed in the morning in a room at 22°C after a 15-min rest and an overnight fast. 
Pulse wave velocity (PWV) assessment
Two pulse waves were obtained transcutaneously at the base of the neck for the right common carotid artery and over the right femoral artery. Transit time was measured as the time between the foot of the pulse wave and the foot of the R wave. Pulse transit time was determined as the average of ten consecutive beats. Time delay (t) was calculated as the difference between these two transit times. The distance (d) traveled by the pulse wave was measured over the body surface as the distance between two recording sites. Pulse wave velocity was calculated as PWV = d
(meters)/t (seconds).
Augmentation index (AIx)
The examination was performed using the applanation tonometry -Applanation (SphygmoCor system created by the Australian company AtCorMedical).
The test was performed in a lying position after a 5-min adaptation with the inner side of the hand facing upward. The tonometer head was placed on the wrist at the most palpable pulse. The system processed a registered pulse wave of the radial artery and marked the pulse curve in the ascending aorta.
The analyzed susceptibility of the vessels was defined by the following parameters: central systolic and diastolic blood pressure levels (aortic SP and DP), central pulse pressure (aortic PP) and the value of the index gain (AIx).
Statistical analysis
Statistical analysis was performed using MedCalc for Windows, version 10.0. All of the text and table results are expressed as means ± standard deviation (SD) or as a number (percentage). The normal distribution result was analyzed using the Kolmogorov-Smirnov test. In the case of abnormal distribution, a logarithmic transformation was used.
The baseline clinical parameters and the results of the ancillary investigations were compared using the two-sample t-tests for normally distributed continuous variables (Student's ttest); in the case of an abnormal distribution, the Mann-Whitney U test was used. Categorical variables were compared using the χ 2 test. The Spearman rank-order test or Pearson correlations were used to determine the relationship between the variables. Multivariable linear regression was used to assess the independent predictors of the adipokine levels; parameters that were associated with plasma adipokines at the level of p < 0.1 on the univariate analysis were analyzed. A value of p < 0.05 was considered statistically significant.
RESULTS
Clinical data
The clinical characteristics of AS patients and controls did not reveal any significant differences (Table 1 ).
There were no significant differences in LVESV, LVEDV, LVEF as well as in CO and the cardiac index (CI) between the patients with AS and the control group (CG). LVMI was obviously significantly higher in the AS group (150.4 ± 32.6 vs. 115.2 ± 21.7 g/m 2 ). The AV annulus was significantly smaller in the AS group (21.5 ± 1.9 vs. 22.9 ± 2.1 mm, p = 0.013). The mean maximum AV gradient (Pmax) in the AS group was 95.8 ± 24.7 mm Hg while the mean gradient (Pmean) was 58.6 ± 16.6 mm Hg. The indexed EOA was calculated for 0.37 ± 0.08 cm 2 /m 2 in the AS group (Table 2) .
There were no significant differences observed in the FMD value between the AS and the CG.
There were also no differences in the BAd. However, the FMDxBAd index remained significantly higher in the CG.
There were also no significant differences in the pulse wave velocity between the two examined groups. Aortic systolic, diastolic pressure and pulse were insignificantly higher in the CG. Value of the index and the gain remained same in both groups (Table 3) .
Clinical data -PLFLG AS vs. NFHG AS
The mean age of both groups remained similar (68.5 ± 7.9 for PLFLG AS vs 68. There were no noticeable differences in PWV (7.5 ± 3.3 vs. 6.5 ± 2 m/s) and in FMD (15.3 ± 11
vs. 18.6 ± 10 %).
No significant differences were observed between all adipokine levels in patients with PLFLG AS vs. NFHG AS.
Serum adipokines levels in the study group and controls
There were no significant differences in the serum adiponectin, leptin, visfatin and resistin concentrations in the AS and CG (Table 4) .
Serum adipokines levels in the study group regarding clinical characteristics
Patients with AS and co-existing CAD were characterized by decreased serum adiponectin (9.9 ± 5.5 vs. 12.7 ± 5.8 μg/mL, p = 0.040) and leptin (8.3 ± 7.8 vs. 21.6 ± 17.1 ng/mL, p < 0.001) levels compared to subjects without CAD. There were no significant differences invisfatin (2.4 ± 2.0 vs. 3.3 ± 2.4 ng/mL, p = 0.074) and resistin levels (5.00 ± 4.2 vs. 7.28 ± 6.1 ng/mL, p = .102) (Table 5 ).
There were no significant differences in serum adipokines concentrations between patients with concomitant HA. Patients with AS and DM had an insignificantly lower adiponectin level (10 ± 5.9 vs. 12.26 ± 5.6, p = 0.052 µg/mL) ( Table 5 ).
There were also no significant differences in the serum adipokine concentrations between patients with PLFLG AS and NFHG AS (Table 5) .
Regression analysis
The Table 6 ).
Leptin levels correlated with BMI (r = 0.456, p < 0.001), body fat percentage (r = 0.522, p < 0.001) and iEOA (r = -0.290, p = 0.019) ( Table 6 ).
Multivariate regression analysis indicated age (F = 3.02; p = 0.015) and the E/E' index (F=0.87, p = 0.032) as independent predictors of the adiponectin level in the AS group.
DISCUSSION
In the population with AS with preserved EF, some clinical and metabolic indices may play a pivotal role for the progression of the disease and its symptomatology. This is why the serum adipokines concentrations were compared between AS patients and the controls -there were no differences observed. Moreover, the hypothesis that the CAD, HA, DM, vascular parameters influenced the adipokine serum levels was verified. This verification was a negative value in regard to the HA, DM and vascular indices. Patients with AS and co-existing CAD were characterized by decreased adiponectin and leptin levels compared to the subjects without CAD. This is an important finding of the study, especially that low serum levels of adiponectin have been recognized as a risk factor for atherosclerotic disease [22] . It should be noted that the protective mechanism of adiponectin, which has an influence on the progression of atherosclerosis and is associated with increasing apolipoprotein A1 and high-density lipoprotein cholesterol, which have beneficial effects on lipid metabolism [23] .
When discussing the role of adiponectin in AS patients, we may take into account the data that describes the adiponectin levels in non-AS patients. In the literature, there are mainly data on adiponectin levels in patients with CAD [24, 25] or metabolic disorders [26] but limited data on the role of adiponectin in AS pathogenesis. Low adiponectin concentrations are well documented in patients with CAD [24] . Low adiponectin contributes to coronary plaque vulnerability [25] . In this study, patients with AS and co-existing CAD were characterized by decreased serum adiponectin and leptin levels compared to subjects without CAD. It was suspected that the same CAD-related mechanism of hypoadiponectinemia was present in the presented group.
The available data on the role of adipokines in AS are limited to some problems. Recently, Gucuk et al. [27] showed, similar to the present findings, that there is no relationship between the adiponectin levels and calcific AV disease. In contrast, Kolasa-Trela et al. [28] published an article suggesting that adipokines may be involved in the progression of AS. In 2010, Mothy et al. [29] observed that older patients with AS had a higher plasma level of resistin, which was associated with the degree of valvular calcification and inflammation. In their next paper, they showed that adiponectin may play a protective role against the inflammatory process and progression of calcific aortic valve disease [30] . They hypothesized that adiponectin might be partly responsible for the association between metabolic syndrome and calcific aortic valve disease. [19, 20] . Although our subpopulation with PLFLG AS had a limited number of patients, it was representative of the above-mentioned characteristics. Regardless of different clinical characteristics of NFHG and PLFLG patients, there were no differences in adipokines concentrations in these groups.
Adiponectin, and also leptin concentrations, correlated with standard obesity indices (BMI, body fat%). This observation is in concordance with previous data. It was demonstrated that low-level adiponectin subjects were characterized by a significantly higher prevalence of some cardiometabolic comorbidities (obesity, visceral obesity, DM, insulin resistance, LVH, metabolic syndrome, CAD) [26, 31, 32] .
Interesting relationships were observed with regard to the adiponectin levels. Adiponectin levels correlated positively with age and negatively with BMI, body fat, LVMI, SVi and the E/E' index.
Multivariate regression analysis confirmed that age and the E/E' index were independent predictors of the adiponectin level in the AS group. Thus, the diastolic dysfunction that is typical for AS influenced adiponectin concentration.
Stojanovic et al. [31] , similar to the present findings, found that adiponectin levels correlated with age, BMI and the E/E' index in patients with metabolic syndrome and/or CAD. On the other hand, in patients with hypertrophic cardiomyopathy, plasma adiponectin levels were associated with an impaired LV systolic function but only slightly with E/E' index [33] .
Positive correlations were found in leptin levels with BMI and body fat%. Generally, leptin, which is a mediator of the long-term regulation of energy balance, suppresses food intake [34] .
Subjects with high plasma leptin levels have a better prognosis, thus suggesting a protective role of leptin in overweight/mild obesity [35] . On the other hand, overweight and obesity are associated with hyperleptinemia secondary to an impaired sensitivity of leptin receptors [36] . Recently, Karmazyn et al. [37] concluded that leptin is a cardiac hypertrophic factor and hyperleptinemia is associated with cardio-vascular risk, especially as it pertains to heart failure. This can be of importance in regards to AS-mediated hypertrophy and/or CAD. As presented above, the presented subjects with AS and CAD were characterized by increased serum leptin levels compared to AS patients without CAD. Further studies are needed to evaluate these interesting concepts.
Regarding adipokines levels, it should also be taken into account the specificity of the population herein-relatively older subjects with AS. Schautz et al. [38] concluded that age-related changes in leptin and adiponectin levels are opposed to each other and are partly independent of adiposity and body fat distribution.
A limitation of the current study could be the relatively small number of patients. It should be stressed, however, that the study was conducted in a prospective fashion, which undoubtedly represents its methodological strength. It is also agreed that the division of the AS cohort into the subgroups PLFLG AS and NFHG AS had limitations related to the number of subjects. However,a well-known PLFLG AS clinical characteristic suggested an abnormal adipokine profile compared to NFHG AS.
An echocardiographic evaluation, especially in older, obese patients, has limitations regarding the LVOT measurements, and finally the AS severity calculation. These problems were apparent, this is why all echocardiographic measurements were done very precisely by an experienced sonographer. Vascular response to sublingual nitroglycerin was not assessed because of the severity of AS. Moreover, adipokines levels were measured at one point only.
CONCLUSIONS
Severe degenerative AS with preserved EF is not associated with any change in the adipokine serum profile. Adipokines serum levels are modified by co-existing atherosclerosis but not the typical cardio-vascular risk factors or the hemodynamic type of AS. The adiponectin serum level in patients with severe AS with preserved EF is related to age and LV diastolic dysfunction.
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